Tirzepatide and semaglutide had a 64% and 34% probability of being cost-effective at a $100,000 per QALY threshold, respectively.

Topline data were announced from a phase 3 trial evaluating garetosmab in adults with fibrodysplasia ossificans progressiva.

Anifrolumab, a type I interferon receptor antagonist, is currently approved under the brand name Saphnelo for IV administration in the treatment of moderate to severe SLE.

Willingness to prescribe estrogen therapy for patients with a history of gynecologic cancer varied by specialty, experience, and sex.

The semaglutide discontinuation rate at 1 year was found to be 52%, and age, sex, and socioeconomic status were associated with it.

Parent-focused early childhood obesity prevention interventions were not significantly associated with differences in offspring BMI.

Delaying MTX initiation by 4 weeks after PCV13 vaccination significantly improved humoral responses in patients with RA, without compromising disease control.